A common prostate cancer mutation retargets an epigenetic complex to force prostate cells down a malignant path, creating a possible therapeutic opportunity in the process.
More powerful than previous methods, a new approach for tagging and harvesting DNA-associated proteins from cells could open deeper insights into transcription control.